About Modnbio 연혁

    연혁

    2020
    • PCT application for “A Composition for Preventing or Treating Retinal Disease Comprising Gypenoside Compound“
      (Registration No. : 10-2045044)
      (PCT No. : PCT/KR2020/006337)
    • Applied for an AI patent for “A system that outputs information and images of
      similar molecules through measurement of similarity between molecules”
    • Applied for DDS patent for “Nano-shell DDS platform based on amphiphilic
      ginseng-derived compounds”
    • Applied for DDS patent for “Amphiphilic ginseng-derived compound-based
      prebiotic shaped particle formation and probiotic delivery platform”
    • SCI Journal “Molecular Drug Discovery of Single Ginsenoside Compounds as a
      Potent Bruton ’s Tyrosine Kinase Inhibitor”
    • Selected as a designated company for military service by a small and
      medium-sized research institute
    2019
    • Started development of new drug development AI platform
    • Started R&D for DDS platform
    • Innovative Small and Medium Business (INNOBIZ) Certification
    • Pproject agreement with Industry-University Cooperation University (LINC)
    • Integrated certification of ISO 9001/14001
    • Patent application for “A Composition for treating neurodegenerative disease comprising a Gypenoside compound as an active ingredient” (Application No. : 10-2019-0070208)
    • Patent application for “A Composition for Preventing or Treating Retinal Disease Comprising Gypenoside Compound“ (Application No. : 10-2019-0056685)
    • Patent Application for "A Composition for Preventing or Treating Bruton's Tyrosine Kinase Mediated Disease Comprising Ginsenoside Compounds" (Application No.: 10-2019-0052360)
    • Signed major representative contract for KOSDAQ listing (KB Securities)
    2018
    • Establishment of living modified organism (LMO) research system
    • Research for Psoriasis, anticancer drug
    • “Patent for “A Composition for Preventing or Treating Inflammasome Mediated Inflammatory Disease Containing Ginsenoside Compounds” (Application No. : 10-1928553) PCT Application(Application No : PCT/KR2019/006677)
    • 5th Generation Antibiotic Research Progress (Based on Identifying Survival Pneumonia Vibrio)
    2017
    • NLRP3 inflammasome inflammatory disease therapeutic substance research
    • BTK-mediated disease therapeutic research
    • Patent for ” Production method of ginsenoside 20(S)-Rg3 and 20(S)-Rh2 using ginsenoside glycosidase” (Application No. : 10-1808749) PCT Application (Application No : PCT/KR2017/014307) Entry into individual countries (USA)
    2016
    • Joint research work agreement with “Korea Biotechnology Research Institute"
    • Won “Small Business Management Award” (Seoul Economic Daily))
    2015
    • Patent for "Mushroom Grower"(Application No. : 10-1708432)
    • Established new drug development research system using natural materials
    2008
    • Established corporation